Ovid therapeutics Inc
Suletud
SektorTervishoid
2.47 2.92
Ülevaade
Aktsiahinna muutus
24h
Min
2.39
Max
2.51
Sissetulek | -27M -17M |
|---|---|
Aktsiakasum | -0.125 |
Kasumimarginaal | -2,366.017 |
Töötajad | 23 |
EBITDA | -5.5M -18M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +122.08% upside |
Järgmine tulemuste avaldamine | 12. aug 2026 |
|---|
Turukapital | -5M 478M |
|---|---|
Eelmine avamishind | -0.45 |
Eelmine sulgemishind | 2.47 |
Ovid therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Ovid therapeutics Inc Prognoos
Hinnasiht
By TipRanks
122.08% tõus
12 kuu keskmine prognoos
Keskmine 5.33 USD 122.08%
Kõrge 7 USD
Madal 4 USD
Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Ovid therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
